Please login to the form below

Not currently logged in

J&J increases holding in Chinese joint venture

According to a company insider, Johnson & Johnson China Investment will buy further shares in Xi'an-Janssen Pharmaceutical

According to an insider, Johnson & Johnson China Investment, a 100-owned subsidiary of US-based Johnson & Johnson (J&J) will buy further shares in Xi'an-Janssen Pharmaceutical from shareholders in the Chinese company.

The financial website TradingMarkets said that the information was leaked from an employee of the pharmaceutical joint venture on 20 November 2007.

J&J is said to be in negotiations with three Chinese shareholders to acquire a 17.2 per cent stake on the basis that the equity structure of the sellers would not change. The acquisition has been approved by China's Ministry of Commerce, according to the insider.

The deal could extend J&J's control in Xi'an-Janssen from 52 to 70 per cent.

J& J China Investment recently acquired 1.8 per cent of Xi'an-Janssen for CNY 78m (approx. USD 10.5m) from Shaanxi Hanjiang Pharmaceutical Group. The other three Chinese shareholders are Shaanxi Pharmaceutical Industry (33.6 per cent), China National Pharmaceutical Industry (5.8 per cent) and China National Pharmaceutical Foreign Trade (3.8 per cent).

Xi'an-Janssen was jointly set up by J&J's subsidiary Belgium-based Janssen Pharmaceutica and the above four Chinese state-owned companies in October 1985.

30th September 2008


Featured jobs

Subscribe to our email news alerts


Add my company
Grace Communications

Grace Communications is a creative agency specialising in healthcare communication and understanding people's personality types....

Latest intelligence

When is it time to rebrand?
The Biosimilar Challenge
How health behaviours and clinical outcomes are related
When HCPs understand patient activation levels they can actively guide patients towards more confident self-management of diverse health concerns....